Meeting
2017 ASCO Annual Meeting
Role of ERBB signaling in RET-rearranged lung cancer and contribution of EGFR amplification to cabozantinib resistance.
Authors
Roger Smith
Northwestern University Feinberg School of Medicine, Chicago, IL
Roger Smith , Alexander E. Drilon , Siddharth Kunte , Ken Suzawa , Takuo Hayashi , Lukas Delasos , Huichun Tai , Tyler Hitchman , Inna Khodos , Marissa Mattar , Shinji Kohsaka , Elisa de Stanchina , William Lockwood , Marc Ladanyi , Romel Somwar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
New Targets and New Technologies
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11583)
DOI
10.1200/JCO.2017.35.15_suppl.11583
Abstract #
11583
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
First Author: Benjamin J. Solomon
Poster
2014 ASCO Annual Meeting
E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC).
First Author: Libor Havel
Poster
2011 ASCO Annual Meeting
Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.
First Author: Y. Y. Janjigian
Poster
2023 ASCO Annual Meeting
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
First Author: Alissa Jamie Cooper